AstraZeneca hit with small fine in Korea over plot to stall generic of lucrative cancer med

For copycat drugmaker Alvogen and British Big Pharma AstraZeneca, the cost of allegedly stalling generics to AZ’s cancer drug Zoladex in Korea is just $1.82 million, or 2.6 billion Korean won.